CoChat

Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. Methods: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). Results: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). Conclusions: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. Registration number: University Hospital Medical Information Network Clinical Trial Registry 000026140.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12094-020-02421-8

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Plasma tryptophan metabolites in patients with non-small cell lung cancer and healthy controls. Responders and non-responders were defined as patients who achieved objective response and those who did not, respectively. Horizontal lines, boxes, and error bars represent the median, the 25th and 75th percentiles, and the minimum and the maximum, respectively
Fig. 1 Plasma tryptophan metabolites in patients with non-small cell lung cancer and healthy controls. Responders and non-responders were defined as patients who achieved objective response and those who did not, respectively. Horizontal lines, boxes, and error bars represent the median, the 25th and 75th percentiles, and the minimum and the maximum, respectivelyCC BY · PubMed Central
Fig. 2 Plasma 3-hydroxyanthranilic acid levels and the efficacy of immune check point inhibitors. (a) Objective response rate according to the status of programmed death-ligand 1 (PD-L1) and/or 3-hydroxyanthranilic acid (3-HAA). (b) Progression-free survival in the patients with high and low 3-HAA levels. High PD-L1 expression and low 3-HAA levels were defined as a tumor proportion score of ≥ 50%, and plasma level of < 35.4 pmol/mL, respectively
Fig. 2 Plasma 3-hydroxyanthranilic acid levels and the efficacy of immune check point inhibitors. (a) Objective response rate according to the status of programmed death-ligand 1 (PD-L1) and/or 3-hydroxyanthranilic acid (3-HAA). (b) Progression-free survival in the patients with high and low 3-HAA levels. High PD-L1 expression and low 3-HAA levels were defined as a tumor proportion score of ≥ 50%, and plasma level of < 35.4 pmol/mL, respectivelyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 91

Metadata

Authors
Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., Suda, T., Maekawa, M., Sugimura, H., & Takada, A.
Affiliations
  • Hamamatsu University (JP)
  • Shimadzu (Japan) (JP)
  • Shizuoka City Shimizu Hospital (JP)
  • Hamamatsu University School of Medicine (JP)
Corresponding author
Karayama, M.
Venue
Clinical and Translational Oncology
Published
2020-06-12
Volume
23
Issue
2
Pages
418-423
ISSN
  • 1699-048X (ISSN-L)
  • 1699-3055
OpenAlex
W3034797925
Cited by
84
References
24
Citations by year
2026: 9 · 2025: 14 · 2024: 14 · 2023: 12 · 2022: 27 · 2021: 8
FWCI
4.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical & Translational Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (20K07823, 19K17631, 19K17632)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
tryptophan metabolites, immune checkpoint inhibitors, non-small cell lung cancer, biomarkers, 3-hydroxyanthranilic acid, xanthurenic acid, tryptophan, treatment response prediction, progression-free survival, plasma metabolites
MeSH terms
Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Prospective Studies, Regression Analysis, ROC Curve, Sensitivity and Specificity, Tryptophan, Xanthurenates, 3-Hydroxyanthranilic Acid, Biomarkers, Treatment Outcome, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. https://app.cochat.ai/papers/10.1007/s12094-020-02421-8
The paper
Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., Suda, T., Maekawa, M., Sugimura, H., & Takada, A. (2021). Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-020-02421-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.